

Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group

Sarah S. Long, MD
Chair, Maternal/Pediatric RSV Work Group

ACIP Meeting

June 28, 2024

Two products are recommended to protect infants and young children from RSV lower respiratory tract disease

- RSV prevention in infants during their first RSV season (i.e., aged <8 months)
 - To protect infants in their first season, either maternal RSV vaccination (Abrysvo, Pfizer), or use of nirsevimab (Beyfortus, Sanofi and AstraZeneca) in the infant is recommended to prevent RSV lower respiratory tract disease
 - Administration of both products is not needed for most infants
- Children ages 8–19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive one dose of nirsevimab

Timing of RSV vaccine and nirsevimab




Figure represents recommended timing of immunization product deployment for most of the continental U.S. In jurisdictions with seasonality that differs from most of the continental United States (e.g., Alaska, jurisdictions with tropical climates), providers should follow state, local, or territorial guidance on timing of administration

Timing of administration of maternal Pfizer RSV vaccine (Abrysvo) and nirsevimab (Beyfortus)

Maternal RSV vaccine

- For pregnant people at 32–36 weeks' gestation, vaccinate using seasonal administration (meaning **September–January** in most of the United States)

Nirsevimab¹

- For infants <8 months of age, immunize shortly before season onset (e.g., October)
- For infants born during October-March, immunize within 1 week of birth

Vaccine administration errors reported in young children and pregnant people



January 22, 2024

Information on Respiratory Syncytial Virus (RSV) Vaccine Administration Errors in Young Children and Pregnant People

<u>Information on Respiratory Syncytial Virus (RSV) Vaccine Administration</u> <u>Errors in Young Children and Pregnant People</u>

Administration of the GSK Respiratory Syncytial Virus Vaccine to Pregnant Persons in Error - PubMed (nih.gov)

<u>Incorrect Administration of Adult RSV Vaccines to Young Children - PubMed (nih.gov)</u>

- Multiple products introduced in the same season created confusion among healthcare workers as to which groups were eligible for which immunizations
- Rare reports of administration errors were received by the Vaccine Adverse Events Reporting System (VAERS)
 - Reports of pregnant persons receiving Arexvy (GSK's vaccine for older adults)
 - Reports of children receiving RSV vaccine instead of monoclonal antibody products (e.g., nirsevimab)
 - Wrong dose (nirsevimab) administered
- CDC made additional resources available and increased education efforts with healthcare providers

Work group members (external)

ACIP Members

Sarah Long (chair)

Oliver Brooks

Camille Kotton

Denise Jamieson

Liaisons

James McAuley (IDSA)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O'Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

Dana DeShon (NAPNAP)

Ex Officio Members

Lucia Lee (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Yugenia Hong-Nguyen (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

Matthew Clark (IHS)

Consultants

Cody Meissner (Dartmouth Geisel School of Medicine)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Daniel Feikin (World Health Organization)

Kevin Ault (Western Michigan University)

Pablo Sanchez (Nationwide Children's Hospital)

GRADE/EtR Consultants

Doug Campos-Outcalt

Rebecca Morgan

Work group members (CDC)

<u>CDC</u>

Katherine Fleming-Dutra (co-lead)	Amber Winn	Ruth Link-Gelles	Demorah Hayes	A. Patricia Wodi	CDC ACIP Staff
Jefferson Jones (co-lead)	Chris Taylor	Megan Wallace	Elizabeth Greene	Christine Olson	Melinda Wharton
Danielle Moulia	Tami Skoff	Monica Godfrey	Monica Patton	Anne Hause	Stephanie Thomas
Meredith McMorrow	Angie Campbell	Karen Broder	Jarrett Gartin	Andrew Leidner	Jessica MacNeil
Mila Prill	Michael Melgar	Naomi Tepper	Dennis Wang	David Shay	
Natalie Thornburg	Amanda Payne	Heidi Moline	Jordan Singleton	Sarah Meyer	
Aron Hall	Noelle Molinari	Hannah Rosenblum	Trang Nguyen Wisard	Kristen Folsom	
Ismael Ortega-Sanchez	Claire Midgley	Derrell Powers	Fatimah Dawood	Julianne Gee	
Melissa Coughlin	Fiona Havers	Raigan Wheeler	John Su	Agustin Lopez	
Jamison Pike	Pragna Patel	Sally Ezra	Michael McNeil	Lakshmi Panagiotakop	oulos
Lauren Roper	Amadea Britton	Manisha Patel			

Agenda

- Implementation and uptake of nirsevimab and maternal RSV vaccine Dr.
 Shannon Stokley (CDC/NCIRD)
- Maternal RSV vaccine safety surveillance Dr. Pedro Moro (CDC/NCEZID)
- Summary of effectiveness of nirsevimab in infants Dr. Amanda Payne (CDC/NCIRD)
- Work Group considerations Dr. Jefferson Jones (CDC/NCIRD)

Thank you

For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

